ArticlemBio2020
Romo1-Derived Antimicrobial Peptide Is a New Antimicrobial Agent against Multidrug-Resistant Bacteria in a Murine Model of Sepsis.
Article in mBio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 54 citations in OpenAlex.
- Antimicrobial peptides for bacterial infections and their biomedical applications.Discover nano · 2026Review
- Model Lipid Bilayers as Platforms for Replicating Bacterial Membranes: A Study of Dynamics and Structural Heterogeneity.The journal of physical chemistry. B · 2026Article
- PLGA nanoparticles loaded with recombinant antimicrobial protein PIP significantly improves the survival state and pathological damage caused by ETEC O8-induced sepsis in mice.Frontiers in veterinary science · 2026Article
- Synergistic Alleviation of Inflammatory Cytokine Storms in Sepsis Rats by Low-Intensity Pulsed Ultrasound and Imipenem.Mediators of inflammation · 2026Article
- AMPs as Host-Directed Immunomodulatory Agents against Skin Infections Caused by Opportunistic Bacterial Pathogens.Antibiotics (Basel, Switzerland) · 2024Review
- A Comprehensive Review of Recent Research into the Effects of Antimicrobial Peptides on Biofilms-January 2020 to September 2023.Antibiotics (Basel, Switzerland) · 2024Review
- The early life immune dynamics and cellular drivers at single-cell resolution in lamb forestomachs and abomasum.Journal of animal science and biotechnology · 2023Article
- Construction of nano slow-release systems for antibacterial active substances and its applications: A comprehensive review.Frontiers in nutrition · 2023Review
- Anti-inflammatory effect of ApoE23 onOpen medicine (Warsaw, Poland) · 2023Article
- A Novel Antimicrobial Peptide SpampcinInternational journal of molecular sciences · 2022Article
- Lights and Shadows on the Therapeutic Use of Antimicrobial Peptides.Molecules (Basel, Switzerland) · 2022Review
- Identification of Bacterial Membrane Selectivity of Romo1-Derived Antimicrobial Peptide AMPR-22 via Molecular Dynamics.International journal of molecular sciences · 2022Article
- Intracellular mechanism of antimicrobial peptide HJH-3 againstRSC advances · 2022Article
- Designing Self-Assembling Chimeric Peptide Nanoparticles with High Stability for Combating Piglet Bacterial Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Review
- Multiple roles of ribosomal antimicrobial peptides in tackling global antimicrobial resistance.Royal Society open science · 2022Article
- New Scabimycins A-C Isolated fromMolecules (Basel, Switzerland) · 2021Article
- Antimicrobial Peptides: A Potent Alternative to Antibiotics.Antibiotics (Basel, Switzerland) · 2021Review
- Elucidating the mechanism by which synthetic helper peptides sensitize Pseudomonas aeruginosa to multiple antibiotics.PLoS pathogens · 2021Article
- Peptides Affecting the Outer Membrane Lipid Asymmetry System (MlaA-OmpC/F) Reduce Avian Pathogenic Escherichia coli (APEC) Colonization in Chickens.Applied and environmental microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To overcome increasing bacterial resistance to conventional antibiotics, many antimicrobial peptides (AMPs) derived from host defense proteins have been developed. However, there are considerable obstacles to their application to systemic infections because of their low bioavailability. In the present study, we developed an AMP derived from Romo1 (AMPR-11) that exhibits a broad spectrum of antimicrobial activity. AMPR-11 showed remarkable efficacy against sepsis-causing bacteria, including multidrug-resistant strains, with low toxicity in a murine model of sepsis after intravenous administration. It seems that AMPR-11 disrupts bacterial membranes by interacting with cardiolipin and lipid A. From the results of this study, we suggest that AMPR-11 is a new class of agent for overcoming low efficacy in the intravenous application of AMPs and is a promising candidate to overcome multidrug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.